Antioxidant treatment for heart failure: friend or foe?
Increasing studies demonstrate a pivotal role for oxidant stress in the pathophysiology of heart failure (HF). Recent meta-analyses also reveal the potential pitfall of a mono-dimensional antioxidant approach. This review article summarizes the main biological pathways involved in oxidant stress and HF, the possible deleterious nature of certain antioxidant monotherapy and proposes potential antioxidant strategies necessary to challenge specific HF aetiology and progression.
Thomson
M J
MJ
Division of Cardiac and Vascular Sciences, Cardiovascular Biology Research Centre, St George's, University of London, London, UK.
Frenneaux
M P
MP
Kaski
J C
JC
D000818:Animals; D000975:Antioxidants / Q000009:adverse effects* / Q000502:physiology; D006333:Heart Failure / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007527:Isoenzymes / Q000502:physiology; D051379:Mice; D009569:Nitric Oxide / Q000502:physiology; D019001:Nitric Oxide Synthase / Q000502:physiology; D018384:Oxidative Stress / Q000502:physiology*; D014810:Vitamin E / Q000009:adverse effects
D000975:Antioxidants; D007527:Isoenzymes; D014810:Vitamin E; D009569:Nitric Oxide; D019001:Nitric Oxide Synthase